After Piper Sandler and H.C. Wainwright gave Savara (NASDAQ: SVRA) a Buy rating last month, the company received another Buy, this time from Evercore ISI. Analyst Liisa Bayko maintained a Buy rating on Savara yesterday and set a price target of $3.00. The company’s shares closed last Monday at $1.61.
According to TipRanks.com, Bayko is a 4-star analyst with an average return of 13.0% and a 44.3% success rate. Bayko covers the Healthcare sector, focusing on stocks such as Ultragenyx Pharmaceutical, Kiniksa Pharmaceuticals, and Vertex Pharmaceuticals.
Currently, the analyst consensus on Savara is a Strong Buy with an average price target of $3.33, implying an 114.8% upside from current levels. In a report issued on May 14, H.C. Wainwright also maintained a Buy rating on the stock with a $3.00 price target.
See today’s analyst top recommended stocks >>
Based on Savara’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $1,000 and GAAP net loss of $13.74 million. In comparison, last year the company had a GAAP net loss of $15.42 million.
Based on the recent corporate insider activity of 9 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of SVRA in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Savara, Inc. is a clinical-stage specialty pharmaceutical company, which engages in the development and commercialization of novel therapies for the treatment of serious or life-threatening rare respiratory diseases. Its products include AeroVanc, Molgradex, GM-CSF, and Aironite. The company was founded on April 27, 2017 and is headquartered in Austin, TX.
Read More on SVRA: